INT318784

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.33
Pain Relevance 0.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (ZAP70) plasma membrane (ZAP70) cytoplasm (ZAP70)
Anatomy Link Frequency
lymph nodes 1
B lymphocytes 1
ZAP70 (Homo sapiens)
Pain Link Frequency Relevance Heat
cytokine 3 98.78 Very High Very High Very High
tolerance 1 90.96 High High
rheumatoid arthritis 52 78.88 Quite High
antagonist 1 78.24 Quite High
anakinra 1 77.36 Quite High
Inflammation 4 75.92 Quite High
abatacept 2 63.76 Quite High
Adalimumab 1 26.56 Quite Low
Infliximab 1 24.04 Low Low
Etanercept 1 18.80 Low Low
Disease Link Frequency Relevance Heat
Chronic Lymphoid Leukemia 83 99.84 Very High Very High Very High
Disease 49 94.14 High High
Cancer 8 84.00 Quite High
Congenital Anomalies 7 82.66 Quite High
Rheumatoid Arthritis 52 78.88 Quite High
Chromosome Aberrations 1 78.62 Quite High
INFLAMMATION 6 75.92 Quite High
Death 1 26.56 Quite Low
Wasting Syndrome 2 23.80 Low Low
Necrosis 1 22.72 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The discovery of recurrent and prognostic relevant chromosomal aberrations in CLL cells via conventional cytogenetics and fluorescence in situ hybridization (FISH) has introduced the stratification of CLL cases according to the presence or absence of genomic key abnormalities.4,5 Deletions/mutations in chromosome 17p13, the site of the tumor suppressor TP53 (p53 gene), are associated with resistance or early failure after chemotherapy with or without the CD20-antibody rituximab and go along with the most decreased survival of patients.5–10 Once refractory to treatment based on purine analogues, such as fludarabine, patients belong to the worst prognostic category with a median overall survival of less than 12 months.11 Similarly, deletions/mutations in chromosome 11q22–23 (includes the ATM gene locus) correlate with early advanced disease, particular in lymph nodes, shorter time to first treatment and shortened long-term survival after chemotherapy.4,5,12 Other powerful surrogate markers of an unfavorable prognosis are an unmutated status of the immunoglobulin heavy chain variable region genes (IGHV) and an elevated level of ZAP70 expression in CLL cells.13–15 The variety and variability of numerous other available biomarkers of prognosis reflect the clinical and biological heterogeneity of CLL.
Gene_expression (expression) of ZAP70 in lymph nodes associated with chronic lymphoid leukemia, chromosome aberrations, cancer, congenital anomalies and disease
1) Confidence 0.13 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895774 Disease Relevance 0.94 Pain Relevance 0
Some that are currently in development and at the trial stages are agents targeting IL-1, cytokines from the TNF superfamily, IL-15, IL-17, B lymphocytes, IL-12/IL-23, SyK kinase, JAK3 kinase, and inhibitors of osteoclastogenesis.40–51

Chemistry and mechanism of action

Gene_expression (/) of SyK kinase in B lymphocytes associated with cytokine
2) Confidence 0.02 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990387 Disease Relevance 0.39 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox